Cite
HARVARD Citation
Heinen, A. et al. (2021). Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?. Rheumatology. pp. e136-e138. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Heinen, A. et al. (2021). Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?. Rheumatology. pp. e136-e138. [Online].